STUDY PROTOCOL

brought to you by T CORE

BMC Cancer

CrossMark



Randomized phase II study of S-1 dosing schedule for resected colorectal cancer

Chu Matsuda^{1†}, Mamoru Uemura^{2,7†}, Ken Nakata³, Tatsushi Shingai⁴, Junichi Nishimura², Taishi Hata², Masakazu Ikenaga⁵, Ichiro Takemasa², Tsunekazu Mizushima², Takeshi Kato⁶, Masataka Ikeda⁷, Masayuki Ohue⁸, Kohei Murata⁹, Junichi Hasegawa⁵, Taroh Satoh¹⁰, Hirofumi Yamamoto^{2*}, Mitsugu Sekimoto⁷, Riichiro Nezu¹¹, Yuichiro Doki² and Masaki Mori²

Abstract

Background: Postoperative adjuvant chemotherapy for patients with stage III Colorectal cancer (CRC) is now internationally accepted as standard care for improving patient outcomes. The Adjuvant Chemotherapy Trial of S-1 for Colorectal Cancer (ACTS-CC) confirmed the non-inferiority of S-1 to tegafur/urcail/leucovorin in terms of overall survival and disease-free survival in patients with stage III CRC after curative surgery. However, the 6-month completion rate of S-1 treatment was 76.5 % in the ACTS-CC. Therefore, treatment completion remains an unresolved problem.

Methods/Design: A randomized phase II trial was designed to evaluate the efficacy and safety of oral daily administration and alternate-day administration of S-1 as adjuvant chemotherapy in curatively resected stage III CRC. Enrolled patients were assigned to either S-1 daily administration (Arm A) or alternate-day S-1 administration (Arm B). Assigned treatment will start within 8 weeks after surgery. In both arms, S-1 dosing (oral) will be based on body surface area (80 mg/day for body surface area < 1.25 m², 100 mg/day for 1.25–1.5 m², or 60 mg/day for > 1.5 m²). In Arm A, S-1 will be administered orally for 28 days, followed by a 14-day rest. Administration will be conducted for 24 weeks from the date of therapy start. In Arm B, S-1 will be administered orally on alternate days for 28 weeks from the date of the start of therapy. After treatment, all patients will be observed without additional therapy unless recurrent lesions or other cancer lesions occur. The primary endpoint is treatment completion rate. Secondary endpoints include 3-year disease-free survival, compliance, and adverse events.

Discussion: Previously, S-1 alternate-day intake maintained the efficacy of chemotherapy while reducing adverse effects for patients with R0-resected stage II/III gastric cancer. Improvement of chemotherapy completion rate for patients with colorectal cancer will lead to an improved patient prognosis. Therefore, a randomized phase II trial has been designed to examine the efficacy of alternate-day versus current standard daily S-1 administration as adjuvant chemotherapy for R0-resected stage III colorectal cancer.

Trial registration: This study was registered on 18 February 2014 with University Hospital Medical Information Network Clinical Trials Registry: UMIN000013185

Keywords: Colorectal cancer, Randomized phase II, S-1, Dose schedule

Full list of author information is available at the end of the article



© 2016 Matsuda et al. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http:// creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

^{*} Correspondence: hyamamoto@gesurg.med.osaka-u.ac.jp

[†]Equal contributors

²Department of Surgery, Gastroenterological Surgery, Graduate School of Medicine, Osaka University, 2-2 Yamada-oka, Suita City, Osaka 565-0871, Japan

Background

Colorectal cancer (CRC) is the second most common cancer in Japan, affecting over 100,000 individuals [1]. The Japanese Society for Cancer of the Colon and Rectum (JSCCR) reported recurrence rates of 3.7 % for stage I disease, 13.3 % for stage II disease, and 30.8 % for stage III [2]. Postoperative adjuvant chemotherapy for patients with stage III CRC is now internationally accepted as standard care for improving patient outcomes. The 2010 JSCCR guidelines recommend four regimens as adjuvant therapy for stage III CRC: i.v. 5-fluorouracil/leucovorin, oral tegafur-uracil/leucovorin, capecitabine, and FOL-FOX (5-fluorouracil/leucovorin plus oxaliplatin) [2].

S-1 is an oral anticancer agent containing tegafur, gimeracil, and oteracil potassium in a molar ratio of 1:0.4:1 [3]. The Adjuvant Chemotherapy Trial of S-1 for Colorectal Cancer (ACTS-CC) confirmed the non-inferiority of S-1 to tegafur/urcail/leucovorin in terms of overall survival and disease-free survival in patients with stage III CRC after curative surgery [4]. However, the 6-month completion rate of S-1 treatment was 76.5 % in the ACTS-CC [4]. Therefore, treatment completion remains an unresolved problem.

Previously, S-1 alternate-day intake maintained the efficacy of chemotherapy while reducing adverse effects, and was tolerable for patients with R0-resected stage II/III gastric cancer [5]. Therefore, we planned a multicenter, cooperative, prospective, randomized phase II study to compare daily and alternate-day S-1 administration as postoperative adjuvant therapy for CRC.

Methods/Design

Registration of the protocol

This study protocol was registered on the website of the University Hospital Medical Information Network, Japan (protocol ID: UMIN000013185) on 18 February 2014. Details are available at: https://upload.umin.ac.jp/ cgi-open-bin/ctr/ctr.cgi?function=brows&action=brows &type=summary&recptno=R000015242&language=J

Digest of the study protocol *Objective*

A randomized phase II trial was designed to evaluate the efficacy and safety of oral daily administration and alternate-day administration of S-1 as adjuvant chemotherapy in curatively resected stage III CRC. This study protocol was approved by the Institutional Protocol Review Board of Osaka General Medical Center (the affiliation of the Principal Investigator) and other participating institutions (Additional file 1).

Study setting

This study is a multi-institutional, prospective, randomized controlled trial that will begin on 1 April, 2014.

Study support

This study is supported by a grant from The Supporting Center for Clinical Research and Education (Osaka, Japan), a nonprofit foundation.

Endpoints

The primary study endpoint is treatment completion rate. Secondary endpoints include 3-year disease-free survival, overall survival, compliance, and adverse events defined by the Common Terminology Criteria for Adverse Events v.4.0 [6].

Eligibility criteria

Patients who received curative resection for histopathologically demonstrated stage III (Japanese Classification of Colorectal Cancer 8th edition [7]) colon or rectosigmoid adenocarcinoma were eligible to participate in this study. The main eligibility criteria were: age 20–80 years, starting chemotherapy within 8 weeks after surgery, having an Eastern Cooperative Oncology Group performance status of 0–1, adequate oral intake, preserved major organ functions, and the ability to provide informed consent.

Patients were excluded if they had a previous history of therapy for stage III CRC (except surgery), previous or concomitant CRC (except carcinoma *in situ*), an active malignancy within 5 years, a history of severe anaphylaxis or allergies to any drug, significant active illness that would preclude protocol treatment, undergoing treatment with fluorocytosine, hepatitis B or C virus infection, or severe mental disease. Pregnant or lactating females were also excluded.


Protocol treatment will begin when the patient fulfills the following criteria: total leukocytes <12,000/mm³, neutrophils \geq 1500/mm³, platelets \geq 100,000/mm³, hemoglobin \geq 9.0 g/dL, aspartate aminotransferase and alanine aminotransferase < 100 IU/L, total bilirubin < 2.0 mg/dL, and creatinine clearance \geq 60 mL/min.

Registration

After confirming eligibility, enrolled patients were randomly assigned to receive either standard daily S-1 therapy (Arm A) or alternate-day S-1 therapy (Arm B) at the MCSGO Data Center. Randomization was performed via a minimization method with stratification by lymph node status (N1 vs. N2 and N3), age (< 70 years vs. \geq 70 years), and institution (Fig. 1).

Treatment methods

Enrolled patients were assigned to either S-1 daily administration (Arm A) or alternate-day S-1 administration (Arm B). Assigned treatment will start within 8 weeks after surgery. In both arms, S-1 dosing (oral) will be based on body surface area (80 mg/day for body Fig. 1 Study design



(n=170)

S-1 80-120mg/body/day for 7 months

week3 week4

 $surface error < 1.25 m^2 = 100 mg/day for 1.25 = 1.5$

surface area < 1.25 m², 100 mg/day for 1.25–1.5 m², or 60 mg/day for > 1.5 m²).

S-1 80-120mg/body/day

(n=170) S-1 80-120mg/body/day for 6 months

Day1 Day8 Day15 Day22 Day29 Day36 Day43

In Arm A, S-1 will be administered orally for 28 days, followed by a 14-day rest. Administration will be conducted for 24 weeks from the date of therapy start. In Arm B, S-1 will be administered orally on alternate days for 28 weeks from the date of the start of therapy (Fig. 1). After treatment, all patients will be observed without additional therapy unless recurrent lesions or other cancer lesions occur.

In each course, treatment will continue when the patients fulfill the following criteria: total leukocytes $\geq 3000/\text{mm}^3$, platelets $\geq 100,000/\text{mm}^3$, aspartate aminotransferase and alanine aminotransferase < 100 IU/L, total bilirubin < 2.0 mg/dL, creatinine ≤ 1.5 mg/dL, and diarrhea and stomatitis no greater than grade 1. If the criteria for continuing treatment are not met, then treatment will be postponed or temporarily suspended until the criteria are satisfied.

Study design and statistical methods

The primary endpoint of this study is treatment completion rate, which is expected to be higher than the treatment completion rate in the ACTS-CC [4] due to alternate-day S-1 administration. Assuming a null hypothesis of 73 % treatment completion and an alternative hypothesis of 83 % treatment completion with one-sided type I error = 0.1 and type II error = 0.2, it was necessary to enroll at least 77 patients in each arm. Assuming 10 % loss to follow-up, we calculated that a total of 170 patients were needed in both treatment arms.

Decision principle

Dav1

2

week

At the beginning of the study, we established the decision principle to be used after trial results are obtained. If the treatment completion rate for alternate-day S-1 administration (Arm B) is better than that for daily S-1 administration (Arm A), and if the 3-year disease-free survival and adverse-events rates of Arm B is improved or approximately the same as those of Arm A, then alternate-day S-1 administration will be recommended as adjuvant chemotherapy for stage III R0-resected CRC patients.

week5

...

Discussion

The feasibility of S-1 treatment as an adjuvant chemotherapy for colorectal cancer was confirmed by ACTS-CC [4], although the protocol treatment completion rate remained 76.5 %. Previously, S-1 alternate-day intake maintained the efficacy of chemotherapy while reducing adverse effects for patients with R0-resected stage II/III gastric cancer [5]. Improvement of chemotherapy completion rate for patients with colorectal cancer will lead to an improved patient prognosis.

Therefore, a randomized phase II trial has been designed to examine the efficacy of alternate-day versus current standard daily S-1 administration as adjuvant chemotherapy for R0-resected stage III colorectal cancer.

Additional file

Additional file 1: All Ethics Committees that approved the study. $(16 \mbox{KB})$

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

All authors (CM, MU, KN, TS, JN, TH, MI (Masakazu Ikenaga), IT, TM, TK, MI (Masataka Ikeda), MO, KM, JH, TS, HY, MS, RN, YD, MM) contributed to the protocol design and reviewed and edited the manuscript. All authors will be responsible for the acquisition of study data. CM, HY, MS, NR, DY, and MM planned, coordinated and conducted the study. CM and MU mainly drafted the manuscript, and all authors were involved in drafting the manuscript. All authors read and approved the final manuscript.

Acknowledgement

This study will be carried out on behalf of the Clinical Study Group of Osaka University (CSGO), Colorectal Group. Study number was assigned as CSGO-CR1401. This study is supported by a grant from The Supporting Center for Clinical Research and Education (SCCRE; Osaka, Japan), a nonprofit foundation. This protocol was reviewed and accepted by the SCCRE.

Author details

 ¹Department of Surgery, Osaka General Medical Center, Osaka, Japan.
²Department of Surgery, Gastroenterological Surgery, Graduate School of Medicine, Osaka University, 2-2 Yamada-oka, Suita City, Osaka 565-0871, Japan.
³Department of Surgery, Sakai City Hospital, Osaka, Japan.
⁶Department of Surgery, Osaka Saiseikai Senri Hospital, Osaka, Japan.
⁵Department of Surgery, Osaka Rosai Hospital, Osaka, Japan.
⁶Department of Surgery, Osaka Rosai Hospital, Osaka, Japan.
⁸Department of Surgery, Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan.
⁹Department of Frontier Science for Cancer and Chemotherapy, Graduate School of Medicine, Osaka University, Osaka, Japan.
¹¹Department of Surgery, Nishinomiya Municipal Central Hospital, Hyogo, Japan.

Received: 21 August 2014 Accepted: 27 May 2015 Published online: 03 June 2015

References

- Cancer statistics in Japan 2012. Available at: http://ganjoho.jp/data/ professional/statistics/backnumber/2012/cancer_statistics_2012.pdf, 2013.
- Watanabe T, Itabashi M, Shimada Y, et al. Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2010 for the treatment of colorectal cancer. Int J Clin Oncol. 2012;17:1–29.
- Shirasaka T, Shimamato Y, Ohshimo H, et al. Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs. 1996;7:548–57.
- Nakamoto Y, Ishiguro IM, Yoshida M, et al. Noninferiority of S-1 to UFT/LV as adjuvant chemotherapy for stage III colon cancer: A randomized phase III trial (ACTS-CC). J Clin Oncol. 2013;(suppl; abstr 3518).
- Tatebe S, Tsujitani S, Nakamura S, et al. Feasibility study of alternate-day S-1 as adjuvant chemotherapy for gastric cancer: a randomized controlled trial. Gastric Cancer, 2013. [Epub ahead of print].
- Common Terminology Criteria for Adverse Events (CTCAE) v4.0. (http:// ctep.cancer.gov/protocolDevelopment/electronic_applications/ ctc.htm#ctc_40). 2011.
- Japanese Society for Cancer of the Colon and Rectum, Japanese Society for Cancer of the Colon and Rectum. Japanese classification of colorectal carcinoma. 8th ed. Kanehara: Japanese Society for Cancer of the Colon and Rectum; 2009.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

) BioMed Central

Submit your manuscript at www.biomedcentral.com/submit